HSDD treatment is something many women look up quietly, often late at night. Maybe your desire for sex has faded, and it upsets you. You are not broken, and you are not alone.
Low desire can feel confusing and lonely. You may wonder if it is your fault, your hormones, or your relationship. Those worries are common, and they are worth taking seriously.
This page keeps things calm and clear. You will learn what HSDD is, how it is diagnosed, and your FDA-approved options. Every fact here comes from FDA labels and named clinical trials.
KEY TAKEAWAYS
- HSDD means low sexual desire that causes you real distress, not just a busy life.
- HSDD is common in premenopausal women and is not a personal failing.
- Vyleesi® (bremelanotide) is the FDA-approved peptide option for HSDD in premenopausal women.
- Vyleesi® can briefly raise blood pressure, so screening for heart health comes first.
- The RECONNECT phase 3 trials studied Vyleesi® in about 1,247 premenopausal women.
What readers want to figure out?
- You want a clear, kind definition of HSDD without the jargon.
- You want to know how a clinician checks for HSDD.
- You want to know your FDA-approved HSDD treatment options.
- You want honest facts on Vyleesi®, the FDA-approved peptide option.
- You want the right questions to ask your own doctor.
What HSDD means?
HSDD stands for hypoactive sexual desire disorder. In plain words, it is low or absent desire for sex. The key part is that it bothers you.
Clinicians look for three things together. The low desire is acquired, which means it is new for you. It is generalized, which means it happens in most settings, not just one.
The third piece is distress. HSDD is defined by the distress it causes you. If low desire does not trouble you, it is not considered a disorder.
This matters because desire naturally rises and falls. Stress, sleep, and life stage all play a part. HSDD is about a lasting change that upsets you.
What HSDD is not?
HSDD is not a low sex drive that never bothers you. People want sex at different levels, and that whole range is normal. HSDD is the distressing drop, not the number itself.
HSDD is also not the same as pain or arousal problems. Those are separate concerns a clinician can check. Naming the right issue helps you get the right care.
HSDD is defined by distress. If low desire truly bothers you, that feeling is valid and worth raising with a clinician.
How common HSDD is, and why it is not your fault?
Low desire with distress is more common than many women think. Research suggests HSDD affects about 1 in 10 women aged 18 to 44 in the United States. So if this is you, you have plenty of company.
Distress is the part that matters most. Many women have quieter seasons of desire and feel fine. HSDD is different because the low desire weighs on you.
Low desire is not a character flaw. It is not laziness, and it does not mean you fail to love your partner. Many real factors can turn desire down.
Naming HSDD can bring relief. A shared experience gets a clear name. That name also opens the door to real, FDA-based options.
How HSDD is diagnosed?
There is no blood test for HSDD. A clinician makes the diagnosis by listening to you. They ask about your desire, your distress, and your history.
Your clinician will likely ask a few gentle questions. They want to understand the full picture, not just one symptom.
Common questions include when the change began. They also ask whether it happens in most settings. They check how much distress it causes you.
They will also look for other causes. Low desire can come from other health issues, medicines, or relationship strain. HSDD is diagnosed when those causes do not fully explain it.
Being honest helps your clinician help you. This is a common, medical conversation for them. You can share as much detail as you feel ready to share.
A quick note on names
You may see more than one label for this. Some newer manuals fold HSDD into a broader term called female sexual interest/arousal disorder. Many clinicians and the FDA still use the name HSDD.
The label matters less than how you feel. What counts is that low desire is troubling you. A clinician can help sort out the right name and next step.
Factors to talk about with your clinician
Desire has many moving parts. Before reaching for any HSDD treatment, it helps to look at the whole picture. Small changes in daily life can matter.
Bring up anything from this list that fits you. Your clinician can help weigh each one.
- Your relationship, including trust, conflict, and how connected you feel.
- Your mood, such as stress, anxiety, or low feelings.
- Medicines you take, since some can lower desire.
- Hormone changes, like those around childbirth or birth control.
- Sleep, since being worn out drains desire for many people.
- Alcohol and general health, which both shape how you feel.
Some of these are reversible. Better sleep or a medicine change can help on its own. A clinician can guide what to try first.
Vyleesi® can briefly raise blood pressure and slow the heart rate, so it is not for people with uncontrolled hypertension or known heart disease.
HSDD treatment: your FDA-approved options
When lifestyle steps are not enough, medicine may help. Two prescription options carry FDA approval for HSDD in premenopausal women. Non-drug support can also play a role.
This page leads with the FDA-approved peptide option, Vyleesi®. It also notes the other approved option and non-drug approaches. peptides.io does not give medical advice or prescribe.
The FDA-approved peptide option: Vyleesi® (bremelanotide)
Vyleesi® is the brand name, and bremelanotide is the active ingredient. It is a small peptide called a melanocortin receptor agonist. The FDA approved it in 2019.
Bremelanotide is a lab-made copy of a natural body peptide. It acts mainly on a target called the melanocortin-4 receptor. Researchers link that receptor to sexual desire.
You may also see bremelanotide called PT-141. The FDA-approved product is Vyleesi®, so that is the name to anchor on. The exact way it helps is not fully known.
What Vyleesi® is approved for?
Vyleesi® has one clear approved use. It is for premenopausal women with acquired, generalized HSDD. The low desire must cause marked distress.
The label also sets firm limits. Vyleesi® is not for postmenopausal women, and it is not for men. It is not meant to boost sexual performance.
Its approval does not cover low desire from other causes. That includes desire problems from another health issue, a relationship conflict, or a medicine. A clinician checks that fit before prescribing.
How Vyleesi® is taken?
Vyleesi® is a shot you give yourself. The dose is 1.75 mg under the skin, using an autoinjector. You place it in your belly or your thigh.
The timing is as-needed, not daily. You use it about 45 minutes before you expect sexual activity. It is made for the moment, not for every day.
There are simple limits to follow. Use no more than one dose in 24 hours. Use no more than eight doses in a month.
Give it a fair trial, but not forever. A prescriber may stop Vyleesi® after 8 weeks if it has not helped. That check protects you from staying on something that is not working.
The blood pressure and heart rate caution
Vyleesi® has one safety point that stands out. It can cause a small, short rise in blood pressure after each dose. It can also slightly slow your heart rate for a while.
These changes are usually brief. They tend to settle within 12 hours of the dose. The label lists this as a warning and precaution, not as a boxed warning.
Because of this, Vyleesi® is not for everyone. The label lists it as contraindicated with uncontrolled high blood pressure. It is also contraindicated with known heart disease.
A clinician checks your heart health before you start. The most common side effects are nausea, flushing, and headache. Most are mild or moderate and ease with time.
What the RECONNECT trials found?
The main evidence for Vyleesi® comes from RECONNECT. This was a pair of phase 3 trials, called Study 301 and Study 302. Both compared Vyleesi® with a placebo over 24 weeks.
About 1,247 premenopausal women were studied across the two trials. All had acquired, generalized HSDD. They used the 1.75 mg shot as needed.
Women taking Vyleesi® had a real rise in sexual desire. On the desire score, the combined gain over placebo was 0.35 (P<0.001). That result was statistically significant.
Women taking Vyleesi® also felt less distress about low desire. On the distress score, the combined result was a drop of 0.33 versus placebo (P<0.001). These numbers apply to the FDA-approved product, Vyleesi®.
Who Vyleesi® may suit, and who it is not for?
Vyleesi® may suit one clear group. She is premenopausal, has acquired and generalized HSDD, and feels real distress. Her blood pressure is well controlled, and her heart is healthy.
Vyleesi® is not right for everyone. It is not for postmenopausal women or for men. It is not for anyone with uncontrolled high blood pressure or known heart disease.
This is a general picture, not a diagnosis. Only a licensed clinician can confirm whether Vyleesi® fits you. Bring your full health history to that talk.
The other FDA-approved option, in brief
There is also a second FDA-approved option for HSDD. It is a daily oral pill called flibanserin (brand name Addyi®). It is taken every day, not as needed.
This page focuses on the peptide option, Vyleesi®. The daily pill has its own FDA label, uses, and cautions. Your clinician can review it with you if it may fit.
Non-drug approaches
Medicine is not the only path. Counseling and sex therapy help many women and couples. They may ease stress, improve connection, and support desire over time.
Fixing reversible causes can help too. That may mean better sleep, less alcohol, or reviewing a medicine with your clinician. Often the best plan mixes a few of these steps.
HSDD treatment options at a glance
Here are the FDA-approved options side by side. Use this to frame a talk with your clinician. It does not replace medical advice.
| FDA-approved option | Approved use | How it is taken | Key caution |
|---|---|---|---|
| Vyleesi® (bremelanotide) | Premenopausal women with acquired, generalized HSDD | Subcutaneous shot, as needed, about 45 minutes before activity | Short, transient rise in blood pressure; not for uncontrolled hypertension or known heart disease |
| Flibanserin (Addyi®) | Premenopausal women with acquired, generalized HSDD | Daily oral pill, taken every day | Taken daily, not as needed; see its own FDA label and ask your clinician |
Questions to ask your doctor about HSDD treatment
Good questions help you get good care. Bring this list to your appointment. You can add your own as they come up.
- Does my low desire fit the definition of acquired, generalized HSDD?
- Could a medicine I take, or my birth control, be lowering my desire?
- Should we check my mood, sleep, stress, or hormones first?
- Am I a good fit for Vyleesi® (bremelanotide), and why or why not?
- Is my blood pressure and heart health safe for Vyleesi®?
- How do I use the Vyleesi® autoinjector, and how often can I dose?
- What side effects should I expect, and when should I call you?
- When will we know if a treatment is working or should stop?
- What non-drug options, like counseling, might help me?
- What is the other FDA-approved option, and could it fit me?
Write your questions down before your visit. Clear questions help you and your clinician choose the right HSDD treatment together.
Where to start?
Start with an honest talk, either in person or online. A licensed clinician can confirm HSDD and review your options. Many women now begin this online through telehealth.
Look for a service that uses licensed prescribers and a licensed pharmacy. If Vyleesi® may fit you, you can compare providers on how they operate. That comparison is linked below.
The Bottom Line
HSDD means low sexual desire that causes you real distress. It is common in premenopausal women, and it is not your fault. Naming it opens the door to real options.
Among FDA-approved choices, the peptide option is Vyleesi® (bremelanotide). It is an as-needed shot for premenopausal women with acquired, generalized HSDD. It can briefly raise blood pressure, so heart health is screened first.
Your next step is a talk with a licensed clinician. Bring your questions, and be honest about your distress. peptides.io can help you learn, but it does not give medical advice.
FREQUENTLY ASKED QUESTIONS
HSDD stands for hypoactive sexual desire disorder. It means low or absent sexual desire that causes you real distress. Clinicians look for desire that is acquired, meaning new for you, and generalized, meaning present in most settings. If low desire does not bother you, it is not considered a disorder. HSDD is common and is not a personal failing.
Vyleesi® (bremelanotide) is the FDA-approved peptide option for HSDD. The FDA approved it in 2019 for premenopausal women with acquired, generalized HSDD. It is a small peptide that acts on the melanocortin-4 receptor, which researchers link to sexual desire. You give it as a shot under the skin, as needed, about 45 minutes before sexual activity.
No. Vyleesi® does not carry a boxed warning. Its label lists a small, short rise in blood pressure, with a slight drop in heart rate, as a warning and precaution. These changes usually settle within 12 hours. Because of this effect, Vyleesi® is contraindicated for people with uncontrolled high blood pressure or known heart disease. A clinician checks your heart health first.
RECONNECT was a pair of phase 3 trials, Study 301 and Study 302. About 1,247 premenopausal women with acquired, generalized HSDD were studied over 24 weeks. Women taking Vyleesi® had a significant rise in sexual desire (combined gain 0.35, P<0.001). They also felt less distress about low desire (combined drop 0.33, P<0.001). These results apply to Vyleesi®.
The FDA approved Vyleesi® only for premenopausal women with acquired, generalized HSDD. The label states it is not for postmenopausal women and not for men. It is also not approved to boost sexual performance. Vyleesi® is contraindicated with uncontrolled high blood pressure or known heart disease. If you fall outside the approved group, a clinician can review other options with you.
Yes. A second FDA-approved option for HSDD is a daily oral pill, flibanserin (brand name Addyi®). It is taken every day, not as needed. This page focuses on the peptide option, Vyleesi®. The daily pill has its own FDA label, uses, and cautions. Your clinician can review it with you if it may fit your needs.
Sometimes, yes. Desire is shaped by sleep, stress, mood, alcohol, hormones, and your relationship. Fixing a reversible cause, like poor sleep or a medicine that lowers desire, may help on its own. Counseling and sex therapy may also support desire over time. A clinician can help you decide what to try first, with or without medicine.
No. peptides.io is an independent education platform, not a pharmacy or clinic. It does not give medical advice or prescribe. This page explains what HSDD is and what the FDA-approved options are, so you can talk with a licensed clinician. A clinician confirms the diagnosis and decides if any treatment is right for you.
Keep Reading
Where to get Vyleesi®: compare providers
You know what HSDD is and how Vyleesi® fits. Next, compare licensed providers for Vyleesi® on how they operate, from prescriber model to follow-up and support.
→ Read next: /compare/vyleesi-providers/
SOURCES
1. VYLEESI® (bremelanotide injection) Prescribing Information. US Food and Drug Administration. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
2. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT). Obstet Gynecol. 2019;134(5):899-908. https://pmc.ncbi.nlm.nih.gov/articles/PMC6819021/
3. Goldstein I, Kim NN, Clayton AH, et al. Hypoactive Sexual Desire Disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) Expert Consensus Panel Review. Mayo Clin Proc. 2017;92(1):114-128. https://www.mayoclinicproceedings.org/article/S0025-6196(16)30596-1/fulltext
4. American College of Obstetricians and Gynecologists. Female Sexual Dysfunction. Practice Bulletin No. 213. Obstet Gynecol. 2019;134(1):e1-e18. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2019/07/female-sexual-dysfunction
5. Assessing the Burden of Illness Associated with Acquired, Generalized Hypoactive Sexual Desire Disorder. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC9133974/
6. Vyleesi® (bremelanotide): Uses, Dosage, Side Effects, Warnings. Drugs.com. https://www.drugs.com/vyleesi.html
Last updated: 2026-07-10 · Editorially reviewed by the Peptides.io team
Comments